Company profile: Cadrenal Therapeutics
1.1 - Company Overview
Company description
- Provider of Tecarfarin, a late-stage novel oral anticoagulant targeting a different metabolic pathway than warfarin for patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib). Under development for anticoagulation needs of left ventricular assist device (LVAD) patients and those with Antiphospholipid Syndrome (APS), aiming for safer alternatives to warfarin.
Products and services
- Tecarfarin: A late-stage novel oral anticoagulant engineered for end-stage kidney disease with atrial fibrillation, targeting a different metabolic pathway than warfarin to address anticoagulation in this population
- Anticoagulation therapy for ESKD and AFib: A pathway-targeted Tecarfarin program intended to deliver safer, more effective anticoagulation versus warfarin for end-stage kidney disease patients with atrial fibrillation
- Anticoagulation therapy for LVAD patients: A cardiac-assist device-focused Tecarfarin program engineered to meet LVAD patients’ anticoagulation needs, aiming for a safer alternative to warfarin
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cadrenal Therapeutics
Physidia
HQ: France
Website
- Description: Provider of nephrology and home dialysis medical equipment, tools and training, including the S3 Monitor for daily home hemodialysis, SeCoHD therapy, home delivery of disposables, remote supervision transmitting session data to dialysis centers, and a technical hotline.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Physidia company profile →
Health Logic Interactive
HQ: Canada
Website
- Description: Provider of consumer-focused handheld point-of-care diagnostic devices, developing and commercializing handheld diagnostics for point-of-care use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Health Logic Interactive company profile →
Redsense
HQ: Sweden
Website
- Description: Provider of a hemodialysis blood leak monitoring system using patented fiber optic technology, including the Redsense Alarm System, a disposable sensor patch, and an extension fiber to detect blood contact and alert for needle dislodgement or leakage; offers an automatic off-switch feature for compliant dialysis machines and training and education services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Redsense company profile →
Gambro
HQ: Sweden
Website
- Description: Provider of medical technology developing, manufacturing and supplying products and therapies for kidney and liver dialysis, myeloma kidney therapy, and other extracorporeal therapies for chronic and acute patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gambro company profile →
Renibus Therapeutics
HQ: United States
Website
- Description: Provider of therapeutics to prevent and treat kidney disease, with RBT-1 (single-dose IV before elective cardiac surgery to reduce post-operative complications; Phase 3), Veverimer (oral hydrochloric acid binder for orphan diseases), RBT-3 (iron nanoparticle to restore iron and improve blood product use in cardiac surgery and ER), RBT-9 (anti-inflammatory/antioxidant for COVID-19), and RBT-2 (oral antioxidant/antifibrotic to delay CKD).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Renibus Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cadrenal Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cadrenal Therapeutics
2.2 - Growth funds investing in similar companies to Cadrenal Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cadrenal Therapeutics
4.2 - Public trading comparable groups for Cadrenal Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →